ADC Therapeutics SA (ADCT) Earnings Call Analysis

NYSE · Healthcare · Biotechnology

9/25

Growth 1 Margin 3 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

9
ADC Therapeutics (ADCT) Q2 2026: $18.6M Product Revenue Sustains with Strategic Shift Toward Earlier DLBCL Lines
August 13, 2026
8
ADC Therapeutics (ADCT) Q1 2026: Operating Expenses Down 13% as Zynlanta Awaits Key Lotus 5 Readout
May 04, 2026
7
ADC Therapeutics (ADCT) Q4 2025: Operating Expenses Down 15% as Pipeline Focus Sharpens Ahead of Lotus 5 Data
March 10, 2026
7
ADC Therapeutics (ADCT) Q3 2025: $60M Capital Infusion Extends Runway as Zynlonta Combo Trials Accelerate
November 10, 2025
10
ADC Therapeutics (ADCT) Q2 2025: Lotus 7 Delivers 87% Complete Response Rate, Reshaping DLBCL Market Path
August 12, 2025
9
ADC Therapeutics (ADCT) Q1 2025: Lotus 7 Response Rate Hits 95.5%, Accelerating Compendia Path
July 03, 2025
12
ADC Therapeutics (ADCT) Q4 2024: ZYNLONTA Expansion Drives Strategic Momentum with $250M Cash Runway
March 27, 2025
ADC Therapeutics (ADCT) Q3 2024: Zynlonta Revenue Rises 26% as Pipeline Focus Shifts to Hematology
November 07, 2024
ADC Therapeutics (ADCT) Q2 2024: Operating Expenses Down 23% as Commercial Profitability Reached and Pipeline Advances
August 06, 2024
ADC Therapeutics (ADCT) Q1 2024: $105M Financing Extends Runway as Zynlonta Pipeline Expands
May 06, 2024
ADC Therapeutics (ADCT) Q4 2023: Zynlonta Net Revenue Climbs 17% as Pipeline Refocuses on Hematology and Next-Gen ADCs
March 13, 2024
9
ADC Therapeutics (ADCT) Q3 2023: 23% Cost Cut Reshapes Path After 33% Zinlonta Sales Slide
November 07, 2023
ADC Therapeutics (ADCT) Q2 2023: 17% Workforce Reduction Enables Pipeline Focus as Zynlonta Expands
August 08, 2023
ADC Therapeutics (ADCT) Q1 2023: 17% Workforce Cut Funds Near-Term Pipeline as Commercial Model Shifts
May 09, 2023
ADC Therapeutics (ADCT) Q4 2022: Zinlonta Penetration Hits 35% in Community, Setting Up Expansion
February 28, 2023

Browse all companies